← Back to Clinical Trials
Recruiting NCT06519162

NCT06519162 Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06519162
Status Recruiting
Phase
Sponsor Chungnam National University Hospital
Condition Autoimmune Hepatitis
Study Type OBSERVATIONAL
Enrollment 3,000 participants
Start Date 2024-07-08
Primary Completion 2029-07-08

Eligibility & Interventions

Sex All sexes
Min Age 19 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 3,000 participants in total. It began in 2024-07-08 with a primary completion date of 2029-07-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In this study, we aim to identify gut microbiomes specific to patients with chronic refractory liver disease and to conduct a gut-liver axis study on the pathogenesis and disease progression.

Eligibility Criteria

Inclusion Criteria: * Adults aged 19 years and older diagnosed with autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, non-alcoholic fatty liver disease, or liver abscess, who have consented to participate in this study at Chungnam National University Hospital. * Adults aged 19 years and older, who are cohabitants of patients diagnosed with autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, non-alcoholic fatty liver disease, or liver abscess, and have consented to participate in this study at Chungnam National University Hospital. B. Exclusion Exclusion Criteria: * Individuals under the age of 19. * Patients or guardians who do not consent to participate in the study

Contact & Investigator

Central Contact

Soon Ok Kim

✉ dona3734@cnuh.co.kr

📞 82-42-280-6717

Principal Investigator

Hyuksoo Eun

PRINCIPAL INVESTIGATOR

Chungnam National University Hospital

Frequently Asked Questions

Who can join the NCT06519162 clinical trial?

This trial is open to participants of all sexes, aged 19 Years or older, studying Autoimmune Hepatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06519162 currently recruiting?

Yes, NCT06519162 is actively recruiting participants. Contact the research team at dona3734@cnuh.co.kr for enrollment information.

Where is the NCT06519162 trial being conducted?

This trial is being conducted at Daejeon, South Korea.

Who is sponsoring the NCT06519162 clinical trial?

NCT06519162 is sponsored by Chungnam National University Hospital. The principal investigator is Hyuksoo Eun at Chungnam National University Hospital. The trial plans to enroll 3,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology